Literature DB >> 22391471

Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease.

Aude Rigolet1, Lucile Musset, Odile Dubourg, Thierry Maisonobe, Philippe Grenier, Jean-Luc Charuel, Anthony Behin, Serge Herson, Zahir Amoura, Olivier Benveniste.   

Abstract

Anti-Ku antibodies have been reported in a wide spectrum of autoimmune diseases, sometimes in association with inflammatory myopathies (IM). We studied the clinical, laboratory, and muscle histologic features of all anti-Ku-positive patients detected in our hospital during the last 10 years, as well as their treatment and outcomes. Anti-Ku antibodies were found in 34 patients (0.46% of 20,600 sera positive for antinuclear antibodies), and complete data were available for 30 patients; 86.7% were female, mean age was 49 years (range, 20-73 yr). The most frequent clinical manifestations were arthralgia (77%) and Raynaud phenomenon (53%). Eleven (37%) patients had IM, 8 of them as part of an overlap syndrome defined as IM associated with connective autoimmune disease (5 systemic sclerosis [SSc], 2 Sjögren syndrome (SS), and 1 systemic lupus erythematosus [SLE]). Of 21 patients without IM, 19 had autoimmune diseases (including 6 SLE, 2 SSc, 2 SS, and 2 rheumatoid arthritis), 1 had bronchial neoplasia, and 1 had nephroangiosclerosis. Clinical features of the 9 patients with IM were myalgia (91%), proximal muscle weakness (89%), and dysphagia (36%). All had increased creatine kinase (median, 2210 U/L; range, 194-4073 U/L). Muscle biopsy showed necrosis, inflammation, and positive HLA class I immunostaining. Interstitial lung disease (ILD) was detected on computed tomography (CT) scan in 11 patients (37%) and was significantly more frequent in patients with IM (82% vs. 10.5%, p < 0.001). Fourteen (47%) patients required no immunosuppressive treatment or only a low corticosteroid dose (<15 mg/d, n = 3). A high dose of corticosteroids was more frequently administered in patients with IM (10/11 cases, 80% with associated ILD) than in patients without IM (4/19 cases, 0 with ILD). Complete muscle remission after steroids occurred in 73% of patients with IM. Lung disease was corticoresistant in 6 of 8 (75%) treated cases.Anti-Ku antibodies remain rarely detected, but their presence can be frequently associated with corticosensitive IM and severe, corticoresistant ILD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22391471     DOI: 10.1097/MD.0b013e31824d9cec

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  23 in total

Review 1.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; James D Katz; Olcay Y Jones
Journal:  Rheum Dis Clin North Am       Date:  2013-09-19       Impact factor: 2.670

Review 2.  [Dermatomyositis-specific antibodies].

Authors:  L Bodoki; M Nagy-Vincze; Z Griger; K Dankó
Journal:  Z Rheumatol       Date:  2015-05       Impact factor: 1.372

Review 3.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

Review 4.  The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.

Authors:  Ilaria Cavazzana; Micaela Fredi; Carlo Selmi; Angela Tincani; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

5.  Acute digital ischemia: A rare presentation of antisynthetase syndrome.

Authors:  Jin Ei Chan; Sandeep Palakodeti; Matthew J Koster
Journal:  Eur J Rheumatol       Date:  2017-03-01

6.  The clinicoserological spectrum of inflammatory myopathy in the context of systemic sclerosis and systemic lupus erythematosus.

Authors:  John D Pauling; Sarah Skeoch; Julie J Paik
Journal:  Indian J Rheumatol       Date:  2021-01-18

7.  [Clinical and immunological characteristics of 88 cases of overlap myositis].

Authors:  Y S Xiao; F Y Zhu; L Luo; X Y Xing; Y H Li; X W Zhang; D H Shen
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-18

8.  Serologic phenotypes distinguish systemic lupus erythematosus patients developing interstitial lung disease and/or myositis.

Authors:  Thaisa Cotton; Marvin J Fritzler; May Y Choi; Boyang Zheng; Omid Zahedi Niaki; Christian A Pineau; Luck Lukusa; Sasha Bernatsky
Journal:  Lupus       Date:  2022-08-26       Impact factor: 2.858

Review 9.  Idiopathic inflammatory myopathies - a guide to subtypes, diagnostic approach and treatment.

Authors:  Alexander Oldroyd; James Lilleker; Hector Chinoy
Journal:  Clin Med (Lond)       Date:  2017-07       Impact factor: 2.659

Review 10.  Myositis autoantibodies and clinical phenotypes.

Authors:  Anna Ghirardello; Elisabetta Borella; Marianna Beggio; Franco Franceschini; Micaela Fredi; Andrea Doria
Journal:  Auto Immun Highlights       Date:  2014-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.